Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia

Hum Psychopharmacol. 2005 Jan;20(1):41-5. doi: 10.1002/hup.655.

Abstract

The Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) was examined for its usefulness as a subjective measure of drug-induced parkinsonism and akathisia. Eighty-three subjects were assessed using the LUNSERS, the Simpson-Angus Scale (SAS) and the Barnes Akathisia Rating Scale (BARS), before and after a 6-week treatment with olanzapine. Significant correlations were found between the changes in scores of parkinsonism items of LUNSERS and SAS. The changes in scores of akathisia item (restlessness), extrapyramidal side effects (EPS) subscale and psychic side-effects subscale of LUNSERS were significantly correlated with those of the BARS. 'Shakiness', one item of the EPS subscale of LUNSERS, correctly classified between parkinsonism and non-parkinsonism groups with 81.0% accuracy. A combination of four items included in EPS and psychic side-effect subscales of LUNSERS identified akathisia and non-akathisia groups with 76.2% accuracy. These results suggest that the EPS and psychic side-effect subscales of LUNSERS may be useful in screening for drug-induced parkinsonism and akathisia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Akathisia, Drug-Induced / diagnosis*
  • Akathisia, Drug-Induced / drug therapy
  • Basal Ganglia Diseases / chemically induced
  • Basal Ganglia Diseases / diagnosis
  • Basal Ganglia Diseases / physiopathology
  • Benzodiazepines / adverse effects
  • Benzodiazepines / therapeutic use
  • Comorbidity
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Olanzapine
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / diagnosis*
  • Parkinson Disease, Secondary / drug therapy
  • Patient Participation*
  • Psychiatric Status Rating Scales*
  • Time Factors
  • Treatment Outcome*

Substances

  • Benzodiazepines
  • Olanzapine